Mankind Pharma Limited (MANKIND.BO) Stock Competitors & Peer Comparison
See (MANKIND.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MANKIND.BO | ₹2,529.75 | -0.29% | 1T | 54.79 | ₹46.17 | +0.04% |
| SUNPHARMA.BO | ₹1,867.80 | +0.23% | 4.5T | 41.05 | ₹45.50 | +0.89% |
| SUNPHARMA.NS | ₹1,868.00 | +0.27% | 4.5T | 39.01 | ₹47.88 | +0.89% |
| DIVISLAB.NS | ₹6,747.00 | -0.60% | 1.8T | 69.51 | ₹97.06 | +0.44% |
| DIVISLAB.BO | ₹6,743.15 | -0.62% | 1.8T | 66.65 | ₹101.17 | +0.44% |
| TORNTPHARM.BO | ₹4,514.15 | +1.27% | 1.5T | 71.37 | ₹63.25 | +0.79% |
| TORNTPHARM.NS | ₹4,514.10 | +1.28% | 1.5T | 70.82 | ₹63.74 | +0.79% |
| ZYDUSLIFE.BO | ₹1,112.10 | +2.56% | 1.1T | 22.19 | ₹50.12 | +1.01% |
| ZYDUSLIFE.NS | ₹1,112.20 | +2.46% | 1.1T | 22.20 | ₹50.11 | +1.01% |
| DRREDDY.NS | ₹1,301.30 | +0.82% | 1.1T | 25.33 | ₹51.37 | +0.62% |
Stock Comparison
MANKIND.BO vs SUNPHARMA.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, SUNPHARMA.BO has a market cap of 4.5T. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while SUNPHARMA.BO trades at ₹1,867.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas SUNPHARMA.BO's P/E ratio is 41.05. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, MANKIND.BO is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check SUNPHARMA.BO's competition here
MANKIND.BO vs SUNPHARMA.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, SUNPHARMA.NS has a market cap of 4.5T. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while SUNPHARMA.NS trades at ₹1,868.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas SUNPHARMA.NS's P/E ratio is 39.01. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, MANKIND.BO is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check SUNPHARMA.NS's competition here
MANKIND.BO vs DIVISLAB.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, DIVISLAB.NS has a market cap of 1.8T. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while DIVISLAB.NS trades at ₹6,747.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas DIVISLAB.NS's P/E ratio is 69.51. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, MANKIND.BO is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check DIVISLAB.NS's competition here
MANKIND.BO vs DIVISLAB.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, DIVISLAB.BO has a market cap of 1.8T. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while DIVISLAB.BO trades at ₹6,743.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas DIVISLAB.BO's P/E ratio is 66.65. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, MANKIND.BO is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check DIVISLAB.BO's competition here
MANKIND.BO vs TORNTPHARM.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, TORNTPHARM.BO has a market cap of 1.5T. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while TORNTPHARM.BO trades at ₹4,514.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas TORNTPHARM.BO's P/E ratio is 71.37. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to TORNTPHARM.BO's ROE of +0.27%. Regarding short-term risk, MANKIND.BO is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check TORNTPHARM.BO's competition here
MANKIND.BO vs TORNTPHARM.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, TORNTPHARM.NS has a market cap of 1.5T. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while TORNTPHARM.NS trades at ₹4,514.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas TORNTPHARM.NS's P/E ratio is 70.82. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to TORNTPHARM.NS's ROE of +0.27%. Regarding short-term risk, MANKIND.BO is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check TORNTPHARM.NS's competition here
MANKIND.BO vs ZYDUSLIFE.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while ZYDUSLIFE.BO trades at ₹1,112.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas ZYDUSLIFE.BO's P/E ratio is 22.19. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, MANKIND.BO is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check ZYDUSLIFE.BO's competition here
MANKIND.BO vs ZYDUSLIFE.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while ZYDUSLIFE.NS trades at ₹1,112.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas ZYDUSLIFE.NS's P/E ratio is 22.20. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, MANKIND.BO is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check ZYDUSLIFE.NS's competition here
MANKIND.BO vs DRREDDY.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while DRREDDY.NS trades at ₹1,301.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas DRREDDY.NS's P/E ratio is 25.33. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to DRREDDY.NS's ROE of +0.12%. Regarding short-term risk, MANKIND.BO is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check DRREDDY.NS's competition here
MANKIND.BO vs DRREDDY.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while DRREDDY.BO trades at ₹1,301.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas DRREDDY.BO's P/E ratio is 19.18. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to DRREDDY.BO's ROE of +0.12%. Regarding short-term risk, MANKIND.BO is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check DRREDDY.BO's competition here
MANKIND.BO vs LUPIN.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while LUPIN.NS trades at ₹2,357.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas LUPIN.NS's P/E ratio is 18.46. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to LUPIN.NS's ROE of +0.28%. Regarding short-term risk, MANKIND.BO is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check LUPIN.NS's competition here
MANKIND.BO vs LUPIN.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while LUPIN.BO trades at ₹2,356.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas LUPIN.BO's P/E ratio is 24.97. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to LUPIN.BO's ROE of +0.28%. Regarding short-term risk, MANKIND.BO is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check LUPIN.BO's competition here
MANKIND.BO vs MANKIND.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, MANKIND.NS has a market cap of 1T. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while MANKIND.NS trades at ₹2,528.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas MANKIND.NS's P/E ratio is 54.73. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, MANKIND.BO is less volatile compared to MANKIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check MANKIND.NS's competition here
MANKIND.BO vs AUROPHARMA.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, AUROPHARMA.BO has a market cap of 883.3B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while AUROPHARMA.BO trades at ₹1,535.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas AUROPHARMA.BO's P/E ratio is 26.07. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, MANKIND.BO is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check AUROPHARMA.BO's competition here
MANKIND.BO vs AUROPHARMA.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, AUROPHARMA.NS has a market cap of 882.7B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while AUROPHARMA.NS trades at ₹1,534.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas AUROPHARMA.NS's P/E ratio is 25.46. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, MANKIND.BO is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check AUROPHARMA.NS's competition here
MANKIND.BO vs LAURUSLABS.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, LAURUSLABS.NS has a market cap of 799.5B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while LAURUSLABS.NS trades at ₹1,481.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas LAURUSLABS.NS's P/E ratio is 90.36. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, MANKIND.BO is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check LAURUSLABS.NS's competition here
MANKIND.BO vs LAURUSLABS.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, LAURUSLABS.BO has a market cap of 799.3B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while LAURUSLABS.BO trades at ₹1,480.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas LAURUSLABS.BO's P/E ratio is 90.35. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, MANKIND.BO is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check LAURUSLABS.BO's competition here
MANKIND.BO vs ALKEM.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, ALKEM.NS has a market cap of 647.5B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while ALKEM.NS trades at ₹5,415.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas ALKEM.NS's P/E ratio is 28.11. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to ALKEM.NS's ROE of +0.18%. Regarding short-term risk, MANKIND.BO is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check ALKEM.NS's competition here
MANKIND.BO vs ALKEM.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, ALKEM.BO has a market cap of 646.5B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while ALKEM.BO trades at ₹5,411.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas ALKEM.BO's P/E ratio is 28.09. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to ALKEM.BO's ROE of +0.18%. Regarding short-term risk, MANKIND.BO is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check ALKEM.BO's competition here
MANKIND.BO vs GLENMARK.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, GLENMARK.NS has a market cap of 615B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while GLENMARK.NS trades at ₹2,179.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas GLENMARK.NS's P/E ratio is 45.20. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to GLENMARK.NS's ROE of +0.14%. Regarding short-term risk, MANKIND.BO is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check GLENMARK.NS's competition here
MANKIND.BO vs GLENMARK.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, GLENMARK.BO has a market cap of 614.4B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while GLENMARK.BO trades at ₹2,180.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas GLENMARK.BO's P/E ratio is 45.27. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to GLENMARK.BO's ROE of +0.14%. Regarding short-term risk, MANKIND.BO is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check GLENMARK.BO's competition here
MANKIND.BO vs SUVENPHAR.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, MANKIND.BO is more volatile compared to SUVENPHAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check SUVENPHAR.NS's competition here
MANKIND.BO vs IPCALAB.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, IPCALAB.NS has a market cap of 412.3B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while IPCALAB.NS trades at ₹1,625.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas IPCALAB.NS's P/E ratio is 36.08. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to IPCALAB.NS's ROE of +0.15%. Regarding short-term risk, MANKIND.BO is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check IPCALAB.NS's competition here
MANKIND.BO vs IPCALAB.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, IPCALAB.BO has a market cap of 412.3B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while IPCALAB.BO trades at ₹1,620.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas IPCALAB.BO's P/E ratio is 36.15. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to IPCALAB.BO's ROE of +0.15%. Regarding short-term risk, MANKIND.BO is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check IPCALAB.BO's competition here
MANKIND.BO vs SUVENPHAR.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, MANKIND.BO is more volatile compared to SUVENPHAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check SUVENPHAR.BO's competition here
MANKIND.BO vs AJANTPHARM.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, AJANTPHARM.BO has a market cap of 399.7B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while AJANTPHARM.BO trades at ₹3,188.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas AJANTPHARM.BO's P/E ratio is 39.32. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, MANKIND.BO is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check AJANTPHARM.BO's competition here
MANKIND.BO vs AJANTPHARM.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, AJANTPHARM.NS has a market cap of 398.2B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while AJANTPHARM.NS trades at ₹3,187.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas AJANTPHARM.NS's P/E ratio is 37.71. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, MANKIND.BO is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check AJANTPHARM.NS's competition here
MANKIND.BO vs JBCHEPHARM.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, JBCHEPHARM.NS has a market cap of 359.2B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while JBCHEPHARM.NS trades at ₹2,237.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas JBCHEPHARM.NS's P/E ratio is 50.24. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, MANKIND.BO is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check JBCHEPHARM.NS's competition here
MANKIND.BO vs JBCHEPHARM.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, JBCHEPHARM.BO has a market cap of 358.5B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while JBCHEPHARM.BO trades at ₹2,229.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas JBCHEPHARM.BO's P/E ratio is 50.29. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, MANKIND.BO is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check JBCHEPHARM.BO's competition here
MANKIND.BO vs EMCURE.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, EMCURE.NS has a market cap of 344.5B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while EMCURE.NS trades at ₹1,816.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas EMCURE.NS's P/E ratio is 37.29. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, MANKIND.BO is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check EMCURE.NS's competition here
MANKIND.BO vs WOCKPHARMA.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, WOCKPHARMA.NS has a market cap of 326.7B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while WOCKPHARMA.NS trades at ₹2,010.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas WOCKPHARMA.NS's P/E ratio is 153.58. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to WOCKPHARMA.NS's ROE of +0.05%. Regarding short-term risk, MANKIND.BO is more volatile compared to WOCKPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check WOCKPHARMA.NS's competition here
MANKIND.BO vs WOCKPHARMA.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, WOCKPHARMA.BO has a market cap of 326.7B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while WOCKPHARMA.BO trades at ₹2,010.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas WOCKPHARMA.BO's P/E ratio is 153.61. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to WOCKPHARMA.BO's ROE of +0.05%. Regarding short-term risk, MANKIND.BO is more volatile compared to WOCKPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check WOCKPHARMA.BO's competition here
MANKIND.BO vs PEL.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, MANKIND.BO is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check PEL.NS's competition here
MANKIND.BO vs NEULANDLAB.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, NEULANDLAB.BO has a market cap of 233.5B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while NEULANDLAB.BO trades at ₹18,040.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas NEULANDLAB.BO's P/E ratio is 63.71. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, MANKIND.BO is less volatile compared to NEULANDLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check NEULANDLAB.BO's competition here
MANKIND.BO vs NEULANDLAB.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, NEULANDLAB.NS has a market cap of 232.2B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while NEULANDLAB.NS trades at ₹18,102.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas NEULANDLAB.NS's P/E ratio is 63.69. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, MANKIND.BO is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check NEULANDLAB.NS's competition here
MANKIND.BO vs PPLPHARMA.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, PPLPHARMA.NS has a market cap of 224.1B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while PPLPHARMA.NS trades at ₹168.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas PPLPHARMA.NS's P/E ratio is -68.65. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, MANKIND.BO is less volatile compared to PPLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check PPLPHARMA.NS's competition here
MANKIND.BO vs PPLPHARMA.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, PPLPHARMA.BO has a market cap of 224.1B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while PPLPHARMA.BO trades at ₹168.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas PPLPHARMA.BO's P/E ratio is -68.58. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, MANKIND.BO is less volatile compared to PPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check PPLPHARMA.BO's competition here
MANKIND.BO vs ASTRAZEN.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, ASTRAZEN.BO has a market cap of 212.9B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while ASTRAZEN.BO trades at ₹8,503.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas ASTRAZEN.BO's P/E ratio is 113.65. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to ASTRAZEN.BO's ROE of +0.23%. Regarding short-term risk, MANKIND.BO is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check ASTRAZEN.BO's competition here
MANKIND.BO vs ASTRAZEN.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, ASTRAZEN.NS has a market cap of 212.8B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while ASTRAZEN.NS trades at ₹8,513.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas ASTRAZEN.NS's P/E ratio is 113.42. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to ASTRAZEN.NS's ROE of +0.23%. Regarding short-term risk, MANKIND.BO is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check ASTRAZEN.NS's competition here
MANKIND.BO vs ERIS.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, ERIS.NS has a market cap of 202.4B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while ERIS.NS trades at ₹1,461.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas ERIS.NS's P/E ratio is 32.29. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, MANKIND.BO is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check ERIS.NS's competition here
MANKIND.BO vs ERIS.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, ERIS.BO has a market cap of 202.4B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while ERIS.BO trades at ₹1,459.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas ERIS.BO's P/E ratio is 32.22. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, MANKIND.BO is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check ERIS.BO's competition here
MANKIND.BO vs GRANULES.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, GRANULES.NS has a market cap of 195.3B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while GRANULES.NS trades at ₹788.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas GRANULES.NS's P/E ratio is 32.20. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, MANKIND.BO is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check GRANULES.NS's competition here
MANKIND.BO vs GRANULES.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, GRANULES.BO has a market cap of 195.3B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while GRANULES.BO trades at ₹787.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas GRANULES.BO's P/E ratio is 35.00. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, MANKIND.BO is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check GRANULES.BO's competition here
MANKIND.BO vs CAPLIPOINT.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, CAPLIPOINT.BO has a market cap of 189.4B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while CAPLIPOINT.BO trades at ₹2,492.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas CAPLIPOINT.BO's P/E ratio is 29.61. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, MANKIND.BO is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check CAPLIPOINT.BO's competition here
MANKIND.BO vs CAPLIPOINT.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, CAPLIPOINT.NS has a market cap of 189.3B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while CAPLIPOINT.NS trades at ₹2,490.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas CAPLIPOINT.NS's P/E ratio is 29.66. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, MANKIND.BO is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check CAPLIPOINT.NS's competition here
MANKIND.BO vs COHANCE.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, COHANCE.NS has a market cap of 175.1B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while COHANCE.NS trades at ₹457.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas COHANCE.NS's P/E ratio is 98.03. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to COHANCE.NS's ROE of +0.06%. Regarding short-term risk, MANKIND.BO is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check COHANCE.NS's competition here
MANKIND.BO vs COHANCE.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, COHANCE.BO has a market cap of 174.8B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while COHANCE.BO trades at ₹458.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas COHANCE.BO's P/E ratio is 98.08. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to COHANCE.BO's ROE of +0.06%. Regarding short-term risk, MANKIND.BO is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check COHANCE.BO's competition here
MANKIND.BO vs NATCOPHARM.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, NATCOPHARM.NS has a market cap of 159.9B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while NATCOPHARM.NS trades at ₹892.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas NATCOPHARM.NS's P/E ratio is 11.27. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to NATCOPHARM.NS's ROE of +0.17%. Regarding short-term risk, MANKIND.BO is more volatile compared to NATCOPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check NATCOPHARM.NS's competition here
MANKIND.BO vs NATCOPHARM.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, NATCOPHARM.BO has a market cap of 159.9B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while NATCOPHARM.BO trades at ₹892.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas NATCOPHARM.BO's P/E ratio is 10.39. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to NATCOPHARM.BO's ROE of +0.17%. Regarding short-term risk, MANKIND.BO is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check NATCOPHARM.BO's competition here
MANKIND.BO vs JUBLPHARMA.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, JUBLPHARMA.NS has a market cap of 154B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while JUBLPHARMA.NS trades at ₹972.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas JUBLPHARMA.NS's P/E ratio is 38.81. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to JUBLPHARMA.NS's ROE of +0.06%. Regarding short-term risk, MANKIND.BO is less volatile compared to JUBLPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check JUBLPHARMA.NS's competition here
MANKIND.BO vs JUBLPHARMA.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, JUBLPHARMA.BO has a market cap of 154B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while JUBLPHARMA.BO trades at ₹973.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas JUBLPHARMA.BO's P/E ratio is 38.79. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to JUBLPHARMA.BO's ROE of +0.06%. Regarding short-term risk, MANKIND.BO is less volatile compared to JUBLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check JUBLPHARMA.BO's competition here
MANKIND.BO vs APLLTD.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, APLLTD.NS has a market cap of 152.7B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while APLLTD.NS trades at ₹777.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas APLLTD.NS's P/E ratio is 22.63. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, MANKIND.BO is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check APLLTD.NS's competition here
MANKIND.BO vs APLLTD.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, APLLTD.BO has a market cap of 152.6B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while APLLTD.BO trades at ₹776.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas APLLTD.BO's P/E ratio is 22.61. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, MANKIND.BO is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check APLLTD.BO's competition here
MANKIND.BO vs ALIVUS.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, ALIVUS.NS has a market cap of 137.3B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while ALIVUS.NS trades at ₹1,118.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas ALIVUS.NS's P/E ratio is 24.36. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to ALIVUS.NS's ROE of +0.18%. Regarding short-term risk, MANKIND.BO is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check ALIVUS.NS's competition here
MANKIND.BO vs ALIVUS.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, ALIVUS.BO has a market cap of 137.2B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while ALIVUS.BO trades at ₹1,118.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas ALIVUS.BO's P/E ratio is 24.36. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, MANKIND.BO is more volatile compared to ALIVUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check ALIVUS.BO's competition here
MANKIND.BO vs GLS.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, MANKIND.BO is more volatile compared to GLS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check GLS.NS's competition here
MANKIND.BO vs GLS.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, MANKIND.BO is more volatile compared to GLS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check GLS.BO's competition here
MANKIND.BO vs VIYASH.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, VIYASH.NS has a market cap of 116.1B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while VIYASH.NS trades at ₹265.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas VIYASH.NS's P/E ratio is 66.47. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, MANKIND.BO is less volatile compared to VIYASH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check VIYASH.NS's competition here
MANKIND.BO vs SHILPAMED.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, SHILPAMED.NS has a market cap of 115.6B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while SHILPAMED.NS trades at ₹591.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas SHILPAMED.NS's P/E ratio is 47.52. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to SHILPAMED.NS's ROE of +0.10%. Regarding short-term risk, MANKIND.BO is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check SHILPAMED.NS's competition here
MANKIND.BO vs CAPPL.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, MANKIND.BO is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check CAPPL.BO's competition here
MANKIND.BO vs PGHL.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, PGHL.BO has a market cap of 103.2B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while PGHL.BO trades at ₹6,207.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas PGHL.BO's P/E ratio is 31.52. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to PGHL.BO's ROE of +0.59%. Regarding short-term risk, MANKIND.BO is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check PGHL.BO's competition here
MANKIND.BO vs PGHL.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, PGHL.NS has a market cap of 103B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while PGHL.NS trades at ₹6,203.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas PGHL.NS's P/E ratio is 31.54. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, MANKIND.BO is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check PGHL.NS's competition here
MANKIND.BO vs STAR.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, STAR.NS has a market cap of 102.4B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while STAR.NS trades at ₹1,111.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas STAR.NS's P/E ratio is 18.40. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, MANKIND.BO is less volatile compared to STAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check STAR.NS's competition here
MANKIND.BO vs STAR.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, STAR.BO has a market cap of 102.3B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while STAR.BO trades at ₹1,114.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas STAR.BO's P/E ratio is 18.45. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, MANKIND.BO is less volatile compared to STAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check STAR.BO's competition here
MANKIND.BO vs AKUMS.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, AKUMS.NS has a market cap of 94.8B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while AKUMS.NS trades at ₹619.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas AKUMS.NS's P/E ratio is 37.14. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, MANKIND.BO is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check AKUMS.NS's competition here
MANKIND.BO vs SUDEEPPHRM.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, SUDEEPPHRM.NS has a market cap of 94.6B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while SUDEEPPHRM.NS trades at ₹837.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas SUDEEPPHRM.NS's P/E ratio is 56.15. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, MANKIND.BO is more volatile compared to SUDEEPPHRM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check SUDEEPPHRM.NS's competition here
MANKIND.BO vs SPARC.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, SPARC.BO has a market cap of 76.4B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while SPARC.BO trades at ₹235.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas SPARC.BO's P/E ratio is 4.91. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to SPARC.BO's ROE of +11.09%. Regarding short-term risk, MANKIND.BO is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check SPARC.BO's competition here
MANKIND.BO vs SPARC.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, SPARC.NS has a market cap of 76.2B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while SPARC.NS trades at ₹234.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas SPARC.NS's P/E ratio is 4.91. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to SPARC.NS's ROE of +11.09%. Regarding short-term risk, MANKIND.BO is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check SPARC.NS's competition here
MANKIND.BO vs FDC.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, FDC.NS has a market cap of 67.1B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while FDC.NS trades at ₹412.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas FDC.NS's P/E ratio is 23.81. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, MANKIND.BO is more volatile compared to FDC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check FDC.NS's competition here
MANKIND.BO vs FDC.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, FDC.BO has a market cap of 67.1B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while FDC.BO trades at ₹411.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas FDC.BO's P/E ratio is 23.81. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to FDC.BO's ROE of +0.12%. Regarding short-term risk, MANKIND.BO is more volatile compared to FDC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check FDC.BO's competition here
MANKIND.BO vs AARTIPHARM.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, AARTIPHARM.NS has a market cap of 64.4B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while AARTIPHARM.NS trades at ₹710.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas AARTIPHARM.NS's P/E ratio is 36.90. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to AARTIPHARM.NS's ROE of +0.09%. Regarding short-term risk, MANKIND.BO is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check AARTIPHARM.NS's competition here
MANKIND.BO vs AARTIPHARM.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, AARTIPHARM.BO has a market cap of 64.4B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while AARTIPHARM.BO trades at ₹711.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas AARTIPHARM.BO's P/E ratio is 34.32. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to AARTIPHARM.BO's ROE of +0.09%. Regarding short-term risk, MANKIND.BO is less volatile compared to AARTIPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check AARTIPHARM.BO's competition here
MANKIND.BO vs SUVEN.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, SUVEN.BO has a market cap of 57.9B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while SUVEN.BO trades at ₹258.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas SUVEN.BO's P/E ratio is -21.02. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to SUVEN.BO's ROE of -1.01%. Regarding short-term risk, MANKIND.BO is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check SUVEN.BO's competition here
MANKIND.BO vs SUVEN.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, SUVEN.NS has a market cap of 57.9B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while SUVEN.NS trades at ₹258.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas SUVEN.NS's P/E ratio is -21.31. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to SUVEN.NS's ROE of -1.01%. Regarding short-term risk, MANKIND.BO is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check SUVEN.NS's competition here
MANKIND.BO vs SHILPAMED.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, SHILPAMED.BO has a market cap of 57.8B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while SHILPAMED.BO trades at ₹590.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas SHILPAMED.BO's P/E ratio is 47.43. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to SHILPAMED.BO's ROE of +0.10%. Regarding short-term risk, MANKIND.BO is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check SHILPAMED.BO's competition here
MANKIND.BO vs INNOVACAP.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, INNOVACAP.NS has a market cap of 54B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while INNOVACAP.NS trades at ₹943.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas INNOVACAP.NS's P/E ratio is 38.37. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, MANKIND.BO is more volatile compared to INNOVACAP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check INNOVACAP.NS's competition here
MANKIND.BO vs SEQUENT.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, MANKIND.BO is more volatile compared to SEQUENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check SEQUENT.BO's competition here
MANKIND.BO vs SEQUENT.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, MANKIND.BO is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check SEQUENT.NS's competition here
MANKIND.BO vs ORCHPHARMA.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, ORCHPHARMA.NS has a market cap of 50.2B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while ORCHPHARMA.NS trades at ₹989.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas ORCHPHARMA.NS's P/E ratio is 159.62. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to ORCHPHARMA.NS's ROE of +0.02%. Regarding short-term risk, MANKIND.BO is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check ORCHPHARMA.NS's competition here
MANKIND.BO vs ORCHPHARMA.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, ORCHPHARMA.BO has a market cap of 50.2B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while ORCHPHARMA.BO trades at ₹988.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas ORCHPHARMA.BO's P/E ratio is 67.68. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to ORCHPHARMA.BO's ROE of +0.02%. Regarding short-term risk, MANKIND.BO is less volatile compared to ORCHPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check ORCHPHARMA.BO's competition here
MANKIND.BO vs BLISSGVS.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, BLISSGVS.NS has a market cap of 49.7B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while BLISSGVS.NS trades at ₹470.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas BLISSGVS.NS's P/E ratio is 39.14. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, MANKIND.BO is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check BLISSGVS.NS's competition here
MANKIND.BO vs BLISSGVS.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, BLISSGVS.BO has a market cap of 49.7B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while BLISSGVS.BO trades at ₹469.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas BLISSGVS.BO's P/E ratio is 39.05. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, MANKIND.BO is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check BLISSGVS.BO's competition here
MANKIND.BO vs GUJTHEM.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, GUJTHEM.NS has a market cap of 43.6B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while GUJTHEM.NS trades at ₹400.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas GUJTHEM.NS's P/E ratio is 93.13. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to GUJTHEM.NS's ROE of +0.17%. Regarding short-term risk, MANKIND.BO is more volatile compared to GUJTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check GUJTHEM.NS's competition here
MANKIND.BO vs IOLCP.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, IOLCP.NS has a market cap of 39.1B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while IOLCP.NS trades at ₹133.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas IOLCP.NS's P/E ratio is 28.37. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, MANKIND.BO is less volatile compared to IOLCP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check IOLCP.NS's competition here
MANKIND.BO vs IOLCP.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, IOLCP.BO has a market cap of 39.1B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while IOLCP.BO trades at ₹132.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas IOLCP.BO's P/E ratio is 28.33. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, MANKIND.BO is less volatile compared to IOLCP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check IOLCP.BO's competition here
MANKIND.BO vs RPGLIFE.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, RPGLIFE.NS has a market cap of 38.2B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while RPGLIFE.NS trades at ₹2,307.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas RPGLIFE.NS's P/E ratio is 33.17. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, MANKIND.BO is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check RPGLIFE.NS's competition here
MANKIND.BO vs RPGLIFE.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, RPGLIFE.BO has a market cap of 37.8B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while RPGLIFE.BO trades at ₹2,303.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas RPGLIFE.BO's P/E ratio is 33.13. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, MANKIND.BO is less volatile compared to RPGLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check RPGLIFE.BO's competition here
MANKIND.BO vs GUFICBIO.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, GUFICBIO.NS has a market cap of 37.1B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while GUFICBIO.NS trades at ₹370.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas GUFICBIO.NS's P/E ratio is 57.94. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to GUFICBIO.NS's ROE of +0.10%. Regarding short-term risk, MANKIND.BO is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check GUFICBIO.NS's competition here
MANKIND.BO vs GUFICBIO.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, GUFICBIO.BO has a market cap of 36.9B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while GUFICBIO.BO trades at ₹368.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas GUFICBIO.BO's P/E ratio is 57.54. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to GUFICBIO.BO's ROE of +0.10%. Regarding short-term risk, MANKIND.BO is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check GUFICBIO.BO's competition here
MANKIND.BO vs NOVARTIND.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, NOVARTIND.NS has a market cap of 36.3B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while NOVARTIND.NS trades at ₹1,472.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas NOVARTIND.NS's P/E ratio is 38.97. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, MANKIND.BO is less volatile compared to NOVARTIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check NOVARTIND.NS's competition here
MANKIND.BO vs NOVARTIND.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, NOVARTIND.BO has a market cap of 36.3B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while NOVARTIND.BO trades at ₹1,468.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas NOVARTIND.BO's P/E ratio is 38.88. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, MANKIND.BO is less volatile compared to NOVARTIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check NOVARTIND.BO's competition here
MANKIND.BO vs AARTIDRUGS.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, AARTIDRUGS.NS has a market cap of 34.3B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while AARTIDRUGS.NS trades at ₹375.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas AARTIDRUGS.NS's P/E ratio is 17.56. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to AARTIDRUGS.NS's ROE of +0.14%. Regarding short-term risk, MANKIND.BO is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check AARTIDRUGS.NS's competition here
MANKIND.BO vs AARTIDRUGS.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, AARTIDRUGS.BO has a market cap of 34.2B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while AARTIDRUGS.BO trades at ₹374.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas AARTIDRUGS.BO's P/E ratio is 17.55. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to AARTIDRUGS.BO's ROE of +0.14%. Regarding short-term risk, MANKIND.BO is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check AARTIDRUGS.BO's competition here
MANKIND.BO vs UNICHEMLAB.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, UNICHEMLAB.NS has a market cap of 30.7B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while UNICHEMLAB.NS trades at ₹436.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas UNICHEMLAB.NS's P/E ratio is 12.17. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to UNICHEMLAB.NS's ROE of +0.10%. Regarding short-term risk, MANKIND.BO is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check UNICHEMLAB.NS's competition here
MANKIND.BO vs UNICHEMLAB.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, UNICHEMLAB.BO has a market cap of 30.6B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while UNICHEMLAB.BO trades at ₹436.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas UNICHEMLAB.BO's P/E ratio is 12.17. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to UNICHEMLAB.BO's ROE of +0.10%. Regarding short-term risk, MANKIND.BO is less volatile compared to UNICHEMLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check UNICHEMLAB.BO's competition here
MANKIND.BO vs MOREPENLAB.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, MOREPENLAB.NS has a market cap of 28.7B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while MOREPENLAB.NS trades at ₹52.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas MOREPENLAB.NS's P/E ratio is 30.23. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to MOREPENLAB.NS's ROE of +0.08%. Regarding short-term risk, MANKIND.BO is less volatile compared to MOREPENLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check MOREPENLAB.NS's competition here
MANKIND.BO vs MOREPENLAB.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, MOREPENLAB.BO has a market cap of 28.6B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while MOREPENLAB.BO trades at ₹52.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas MOREPENLAB.BO's P/E ratio is 29.22. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to MOREPENLAB.BO's ROE of +0.08%. Regarding short-term risk, MANKIND.BO is less volatile compared to MOREPENLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check MOREPENLAB.BO's competition here
MANKIND.BO vs SOLARA.BO Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, SOLARA.BO has a market cap of 27.9B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while SOLARA.BO trades at ₹578.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas SOLARA.BO's P/E ratio is -342.57. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to SOLARA.BO's ROE of -0.01%. Regarding short-term risk, MANKIND.BO is more volatile compared to SOLARA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MANKIND.BO.Check SOLARA.BO's competition here
MANKIND.BO vs SOLARA.NS Comparison June 2026
MANKIND.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MANKIND.BO stands at 1T. In comparison, SOLARA.NS has a market cap of 27.9B. Regarding current trading prices, MANKIND.BO is priced at ₹2,529.75, while SOLARA.NS trades at ₹579.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MANKIND.BO currently has a P/E ratio of 54.79, whereas SOLARA.NS's P/E ratio is -342.66. In terms of profitability, MANKIND.BO's ROE is +0.13%, compared to SOLARA.NS's ROE of -0.01%. Regarding short-term risk, MANKIND.BO is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MANKIND.BO.Check SOLARA.NS's competition here